MedPath

Evaluation of the Degradation of Renal Function Post Nephrectomy According to Retinal Vascularisation Parameters

Not Applicable
Recruiting
Conditions
Retinal Vascularisation
Nephrostomy
Interventions
Other: retinal imaging
Other: paraclinical surveillance
Registration Number
NCT04855123
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Brief Summary

Chronic kidney failure in the single remaining kidney is one of the dreaded complications of nephrectomy in patients operated on for cancer-related reasons (1). Indeed, chronic kidney disease (CKD) is associated with major cardiovascular morbidity and mortality (2).

To date, there are few non-invasive methods available to predict the onset and progression of CKD in patients for whom nephrectomy is indicated. Preoperative creatinine and glomerular filtration rate are poor predictors of the subsequent risk of single kidney failure (1). Early predictive markers could help anticipate the management of CKD in patients for whom progression to end-stage renal disease is predictable. Furthermore, such markers could be used as a decision-making aid to specify the type of nephrectomy to be preferred (total versus partial nephrectomy).

The state of microcirculation, particularly retinal, is correlated with the progression of certain conditions such as diabetic nephropathy (3-5). A new technique for evaluating retinal microcirculation called OCT-A (an imaging technique in ophthalmology allowing a precise non-invasive study of the retinal microvascular network) has recently been used by our team to highlight an association between retinal vascularisation and the level of cardiovascular risk in a population of coronary patients without diabetes (6).

We hypothesize that the observation of retinal vascular abnormalities could reflect changes in kidney structure that could underlie chronic renal failure. The aim of this work is thus to evaluate whether the presence of abnormalities in the retinal microvascularisation is 1) predictive of the deterioration in renal function one year after nephrectomy for cancer-related reasons and 2) correlated with renal histological abnormalities.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
42
Inclusion Criteria
  • Adult patient
  • Indication for total nephrectomy for kidney cancer decided with a multidisciplinary oncology consultation
  • Kidney scan images available
  • Patient affiliated to French national health insurance
  • Patient who has given oral consent
Exclusion Criteria
  • Pregnant woman
  • Ophthalmologic history (macular vascular or degenerative diseases, epiretinal membranes, glaucoma)
  • Cannot sit still for 60 minutes
  • Metastatic cancer
  • Single functional kidney before nephrectomy
  • Estimated Glomerular Filtration Flow Rate (CKD-EPI formula) less than 60 mL/min/1.73m2
  • Diabetes type 1 or type 2
  • Proteinuria at inclusion (or in the 3 months prior to inclusion) on sample with a protein/creatinuria ratio greater than 1g/g or over 24 hours greater than 1g/day
  • HIV, HCV or HBV positive serology
  • Patient subject to a measure of legal protection (guardianship, curatorship, etc.)

SECONDARY EXCLUSION CRITERIA

  • Patient with increased pressure during the measurement of the intraocular pressure before dilation
  • Patient with histological abnormalities suggestive of nephropathy (excluding nephroangiosclerosis) or ischemic parenchymal sequelae of renal vein thrombosis in the pathological analysis of the nephrectomy sample

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
patientretinal imaging-
patientparaclinical surveillance-
Primary Outcome Measures
NameTimeMethod
Decline in renal function one year after nephrectomyOne year after nephrectomy

defined in a given patient as the occurrence of a Glomerular Filtration Flow Rate (CKD/EPI equation) of less than 60ml/min/1.73 m2

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chu Dijon Bourgogne

🇫🇷

Dijon, France

© Copyright 2025. All Rights Reserved by MedPath